Stay updated on Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0. This is a minor version update and does not change the study information.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the government funding operating-status notice from the page. The study details and other content remain unchanged.SummaryDifference0.4%

- Check49 days agoChange DetectedOnly non-substantive updates are visible, such as the last update timestamp; the core study details, eligibility criteria, endpoints, and listed locations appear unchanged.SummaryDifference0.4%

- Check70 days agoChange DetectedMajor upgrade: version bumped to v3.2.0 and a prominent funding/operating-status notice added; previous v3.1.0 deletion indicates update to the site’s status messaging.SummaryDifference3%

- Check78 days agoChange DetectedMajor update to page status and versioning: add Results Submitted, Last Update Posted (Estimated), and Revision v3.1.0; remove No Results Posted, Last Update Posted, and Revision v3.0.2, plus the ovarian cancer resource reference.SummaryDifference0.6%

- Check85 days agoChange DetectedSummary of changes: added several future dates and a note about U.S. manufacturing/export; removed several older dates; overall shift highlights origin and new dates.SummaryDifference1%

Stay in the know with updates to Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.